Drilldown: Medicines
Use the filters below to narrow your results.
generic:
3-MMC (1) ·
Butylone (1) ·
Cathinone (1) ·
Colchicine (1) ·
Ephylone (1) ·
Ethcathinone (1) ·
Ethylone (1) ·
Hexedrone (1) ·
Mephedrone (1) ·
Mesalamine (5-aminosalicylic acid, 5-ASA) (1) ·
Methcathinone (1) ·
Methylone (1) ·
Mexedrone (1) ·
N-Ethylhexedrone (1) ·
N-Ethylpentedrone (1) ·
Pentedrone (1)
brand:
classes: (Click arrow to add another value)
mechanism:
None (2) ·
Cathinone analogue; monoamine reuptake inhibitor (2) ·
Monoamine releasing agent (4) ·
Monoamine releasing agent; active ingredient in khat (1) ·
Norepinephrine and dopamine releasing agent (1) ·
Norepinephrine/dopamine releasing agent (1) ·
Norepinephrine/dopamine reuptake inhibitor (1) ·
Serotonin releasing agent; monoamine reuptake inhibitor (1) ·
Serotonin/norepinephrine/dopamine releasing agent (3)
uses:
starting dose:
None (14) ·
Active UC: Lialda 2.4-4.8 g PO once daily, Apriso 1.5 g PO once daily; maintenance 1.2-2.4 g/d; rectal Rowasa enema 4 g HS for distal disease; Canasa 1 g suppository HS for proctitis (1) ·
Acute gout: 1.2 mg PO at first symptom, then 0.6 mg 1 hour later (total 1.8 mg in 1 hour, the FDA-revised regimen); prophylaxis 0.6 mg PO daily or BID; FMF 1-2 mg/d; pericarditis 0.5-0.6 mg BID for 3 months; Lodoco 0.5 mg PO daily for CV risk reduction (1)
preparations:
fda max:
routes:
onset:
duration:
halflife:
bioavailability:
pregnancy:
None (14) ·
Generally considered safe at standard doses; benefits typically outweigh in active IBD.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Used in FMF in pregnancy; otherwise weigh against alternatives.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
Showing below up to 16 results in range #1 to #16.